Intelligent Systems Announces Third Quarter and Year-To-Date 2016 Results
Nov 14, 2016 12:00 pm UTC| Business
NORCROSS, Ga., Nov. 14, 2016 -- Intelligent Systems Corporation (NYSE MKT:INS) announced today its financial results for the three and nine month periods ended September 30, 2016. Revenue was $2,649,000 and $5,844,000...
MediWound Reports Third Quarter 2016 Financial Results
Nov 14, 2016 11:45 am UTC| Business
YAVNE, Israel, Nov. 14, 2016 -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, reports financial...
Argos Therapeutics Reports Third Quarter 2016 Financial Results and Recent Operational Highlights
Nov 14, 2016 11:30 am UTC| Business
- Dr. Richard D. Katz Joined as Chief Financial Officer - - Raised Gross Proceeds of $50 million in Follow-on Offering - - First Patient Dosed in Stage 2 of Adult Eradication Trial of AGS-004 in HIV -- Investor Day...
Gulf Resources Reports Third Quarter 2016 Financial Results
Nov 14, 2016 11:15 am UTC| Business
SHOUGUANG, China, Nov. 14, 2016 -- Gulf Resources, Inc. (Nasdaq:GURE) ("Gulf Resources" or the "Company"), a leading manufacturer of bromine, crude salt and specialty chemical products in China, today announced its...
Pulse Provides Q3 Report and Outlook
Nov 14, 2016 11:13 am UTC| Business
DENVER, Nov. 14, 2016 -- The Pulse Beverage Corporation (“Pulse”) (OTCQX:PLSB), makers of Natural Cabana® Lemonades/Limeades and Coconut Waters, and PULSE® Heart Body Health functional beverages, today provided its Q3...
Annexus Ventures Closes Strategic Investment in RepPro
Nov 14, 2016 11:00 am UTC| Business
SCOTTSDALE, Ariz., Nov. 14, 2016 -- Annexus Ventures, a venture capital firm focused on making early-stage investments in InsureTechand FinTech companies, announced a new strategic investment in Michigan-based developer...
Nov 14, 2016 11:00 am UTC| Business
NEW YORK and MELBOURNE, Australia, Nov. 14, 2016 -- Mesoblast Limited (ASX:MSB) (Nasdaq:MESO)today announced that the Phase 3 trial of its intravenous product candidateMSC-100-IV used as front-line therapy in children...